TGCT
MCID: TST021
MIFTS: 58

Testicular Germ Cell Tumor (TGCT)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Testicular Germ Cell Tumor

MalaCards integrated aliases for Testicular Germ Cell Tumor:

Name: Testicular Germ Cell Tumor 57 73 16 71
Male Germ Cell Tumor 57 73 71
Testicular Teratoma 58 53 16
Testicular Non-Seminomatous Germ Cell Tumor 16 71
Spermatocytic Seminoma, Somatic 57 5
Male Germ Cell Tumor, Somatic 57 5
Embryonal Cell Carcinoma 73 71
Spermatocytic Seminoma 73 71
Seminoma 73 71
Tgct 57 73
Mgct 57 73
Malignant Testicular Non-Seminomatous Germ Cell Tumor 71
Testicular Non-Dysgerminomatous Germ Cell Tumor 58
Non-Dysgerminomatous Germ Cell Tumor of Testis 58
Testicular Non Seminomatous Germ Cell Tumor 58
Non-Seminomatous Germ Cell Tumor of Testis 58
Nonseminomatous Germ Cell Tumors 73
Nonseminomatous Germ Cell Tumor 71
Germ Cell Tumors, Somatic 57
Testicular Tumor, Somatic 57
Germ Cell Tumor, Somatic 5
Embryonal Carcinoma Cell 16
Endodermal Sinus Tumor 73
Teratoma of the Testis 58
Teratoma Testicular 73
Teratoma of Testis 71
Yolk Sac Tumor 71

Characteristics:


Inheritance:

Somatic mutation 57

Prevelance:

Non-Seminomatous Germ Cell Tumor of Testis: 1-9/100000 (Europe) 1-5/10000 (Europe) 58
Testicular Teratoma: <1/1000000 (Europe) 58

Age Of Onset:

Non-Seminomatous Germ Cell Tumor of Testis: Adult 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
two subtypes - seminoma and nonseminoma
occasionally germ cell tumor arise from extra gonadal site (e.g., mediastinum, retroperitoneum, pineal gland)
most common cancer in men aged 15-40 years
highest incidence in men of european descent
risk factors for development of tgct - family history, cryptorchidism , testicular feminization , klinefelter syndrome, previous tgct, gonadal dysgenesis


Classifications:

Orphanet: 58  
Rare urogenital diseases


External Ids:

OMIM® 57 273300
ICD10 via Orphanet 32 C62.1 C62.9
UMLS via Orphanet 72 C0238451
UMLS 71 C0014145 C0036631 C0238451 more

Summaries for Testicular Germ Cell Tumor

OMIM®: 57 Testicular germ cell tumors (TGCTs) affect 1 in 500 men and are the most common cancer in males aged 15 to 40 in western European populations. The incidence of TGCT rose dramatically during the 20th century. Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility, previously diagnosed TGCT, and a family history of the disease. Brothers of men with TGCT have an 8- to 10-fold risk of developing TGCT, whereas the relative risk to fathers and sons is 4-fold. This familial relative risk is much higher than that for most other types of cancer (summary by Rapley et al., 2000). (273300) (Updated 08-Dec-2022)

MalaCards based summary: Testicular Germ Cell Tumor, also known as male germ cell tumor, is related to testicular spermatocytic seminoma and spermatocytoma. An important gene associated with Testicular Germ Cell Tumor is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are p70S6K Signaling and PI3K-Akt signaling pathway. The drugs Granisetron and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include testis, pineal and lymph node, and related phenotypes are azoospermia and elevated alpha-fetoprotein

Orphanet 58 Testicular teratoma: A rare neoplastic disease characterized by the presence of a testicular tumor composed of several, well-differentiated or immature, tissues derived from one or more of the 3 germinal layers. Patients typically present unilateral (occasionally bilateral) painless testicular swelling or a palpable testicular nodule/mass.

Non-seminomatous germ cell tumor of testis: A form of testicular germ cell tumor occurring in the third decade of life with a usually painless unilateral mass in the scrotum or, in some cases, with gynaecomastia and/or back and flack pain. The clinical course is more aggressive than testicular seminomatous germ cell tumors with rapid involvement of blood vessels and a poorer prognosis. Histologically, the tumour can be either undifferentiated (embryonal carcinoma), differentiated (teratoma, yolk sac tumor, choriocarcinoma), or can consist of a mixture of seminomatous and nonseminomatous components.

UniProtKB/Swiss-Prot: 73 A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.

Related Diseases for Testicular Germ Cell Tumor

Diseases in the Testicular Germ Cell Tumor family:

Testicular Germ Cell Tumor 1

Diseases related to Testicular Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 803)
# Related Disease Score Top Affiliating Genes
1 testicular spermatocytic seminoma 32.2 HRAS FGFR3
2 spermatocytoma 32.0 MIR371A LRRC56 KIT HRAS FGFR3
3 germ cell tumor 31.9 TGCT1 STK11 STK10 KIT FGFR3
4 testicular germ cell cancer 31.1 STK11 MIR373 MIR372 MIR371A MIR367 KITLG
5 endodermal sinus tumor 31.0 MIR373 MIR371A KIT
6 thymoma 30.5 LRRC56 KIT HRAS
7 testicular cancer 30.5 STK11 MIR373 MIR372 MIR371A KITLG KIT
8 neurofibromatosis, type i 30.2 KITLG KIT HRAS
9 germ cell cancer 30.2 MIR373 MIR371A MIR302D KITLG KIT
10 childhood germ cell cancer 30.2 MIR371A KITLG
11 ovarian germ cell cancer 30.2 MIR371A KIT
12 dysgerminoma 30.2 MIR371A KITLG KIT
13 gastrointestinal stromal tumor 30.1 KITLG KIT HRAS FGFR3
14 malignant teratoma 30.1 MIR371A KIT
15 mast-cell sarcoma 29.9 KITLG KIT
16 lymphatic system disease 29.9 MIR373 MIR200C MIR145 MIR140
17 testicular disease 29.7 MIR372 MIR371A KITLG KIT
18 brain germinoma 29.7 MIR373 MIR371A KITLG KIT
19 dysgerminoma of ovary 29.6 MIR371A KITLG KIT
20 myeloproliferative neoplasm 29.6 KITLG KIT HRAS FGFR3
21 renal cell carcinoma, papillary, 1 29.6 LRRC56 KIT HRAS FGFR3
22 rectum cancer 29.5 MIR145 MIR140 HRAS
23 suppression of tumorigenicity 12 29.5 MIR145 LRRC56 HRAS
24 gliosarcoma 29.5 LRRC56 HRAS FGFR3
25 thyroid gland anaplastic carcinoma 29.4 MIR145 KIT HRAS
26 noonan syndrome 1 29.4 LRRC56 HRAS FGFR3 BCL10
27 head and neck cancer 29.2 MIR373 MIR145 MIR140 HRAS
28 leukemia, chronic lymphocytic 29.1 MIR373 MIR145 MIR140 LRRC56 KIT HRAS
29 malignant astrocytoma 29.0 MIR373 MIR200C MIR145 MIR140
30 melanoma 29.0 STK11 MIR302D MIR200C MIR140 LRRC56 KITLG
31 hematologic cancer 28.9 MIR200C MIR145 MIR140 KITLG KIT HRAS
32 lung cancer susceptibility 3 28.7 STK11 MIR200C MIR145 MIR140 LRRC56 HRAS
33 lymphoma, non-hodgkin, familial 28.6 MIR373 MIR200C MIR145 MIR140 KITLG BCL10
34 leukemia, acute myeloid 28.1 MIR372 MIR367 MIR302D MIR145 MIR140 LRRC56
35 lung cancer 27.4 STK11 MIR373 MIR372 MIR367 MIR200C MIR145
36 nervous system disease 27.0 MIR373 MIR371A MIR367 MIR302D MIR200C MIR145
37 testicular germ cell tumor 1 11.8
38 childhood endodermal sinus tumor 11.7
39 childhood testicular germ cell tumor 11.7
40 ovarian endodermal sinus tumor 11.6
41 testicular yolk sac tumor 11.6
42 adult endodermal sinus tumor 11.6
43 childhood ovarian endodermal sinus tumor 11.6
44 yolk sac tumor of central nervous system 11.5
45 pigmented villonodular synovitis 11.5
46 childhood cns embryonal cell carcinoma 11.5
47 testicular seminoma 11.5
48 central nervous system endodermal sinus tumor 11.4
49 testis seminoma 11.4
50 testicular germ cell tumor non-seminomatous 11.3

Graphical network of the top 20 diseases related to Testicular Germ Cell Tumor:



Diseases related to Testicular Germ Cell Tumor

Symptoms & Phenotypes for Testicular Germ Cell Tumor

Human phenotypes related to Testicular Germ Cell Tumor:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 azoospermia 30 HP:0000027
2 elevated alpha-fetoprotein 30 HP:0006254
3 teratoma 30 HP:0009792
4 choriocarcinoma 30 HP:0100768
5 embryonal neoplasm 30 HP:0002898

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Genitourinary Internal Genitalia Male:
painless testicular mass

Laboratory Abnormalities:
isochromosome 12p (i(12p))
elevated hcg (choriocarcinoma)
elevated afp (endodermal sinus tumor)
elevated hcg or afp or both (embryonal carcinoma)
azoospermia/oligospermia (present at diagnosis)

Neoplasia:
male germ cell tumors (gct), 2 subtypes -
seminoma
nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor)

Clinical features from OMIM®:

273300 (Updated 08-Dec-2022)

Drugs & Therapeutics for Testicular Germ Cell Tumor

Drugs for Testicular Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
5
Selenium Approved, Investigational, Vet_approved Phase 3 7783-07-5, 7782-49-2 533
6
Tocopherol Approved, Investigational Phase 3 1406-66-2
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Coenzyme M Approved, Investigational Phase 3 3375-50-6 598 23662354
11
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
12
Promethazine Approved, Investigational Phase 3 60-87-7 4927
13
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
14
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
15
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
16
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
17
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Vinblastine Approved Phase 3 865-21-4 241903 13342
20
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
21
Ethinylestradiol Approved Phase 3 57-63-6 5991
22
Polyestradiol phosphate Approved Phase 3 28014-46-2
23
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
24
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
25
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 3 59-02-9, 10191-41-0 2116 14985
26
Ascorbic acid Approved, Nutraceutical Phase 3 50-81-7 54676860 54670067 5785
27
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
28
Racemethionine Approved, Experimental, Investigational, Nutraceutical Phase 3 59-51-8, 63-68-3, 348-67-4 6137
29
Tocotrienol Investigational Phase 3 6829-55-6 9929901
30
Palifosfamide Investigational Phase 3 31645-39-3 100427
31 Neurotransmitter Agents Phase 3
32 Liver Extracts Phase 3
33 Cytochrome P-450 Enzyme Inhibitors Phase 3
34 Vitamins Phase 3
35 Calcium, Dietary Phase 3
36 N-Methylaspartate Phase 3
37 Antioxidants Phase 3
38 Tocotrienols Phase 3
39 Tocopherols Phase 3
40
Etoposide phosphate Phase 3 16760419
41 Antibiotics, Antitubercular Phase 3
42 Dermatologic Agents Phase 3
43 Adjuvants, Immunologic Phase 3
44 Histamine H2 Antagonists Phase 3
45 Keratolytic Agents Phase 3
46 Anti-Bacterial Agents Phase 3
47 Anti-Infective Agents Phase 3
48 Albumin-Bound Paclitaxel Phase 3
49 Antimitotic Agents Phase 3
50 Tubulin Modulators Phase 3

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
2 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
3 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
4 A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
5 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Unknown status NCT01726374 Phase 3 BEP(500)
6 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
7 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
8 INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS Completed NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
9 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
10 A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3 Completed NCT00324298 Phase 3 cisplatin;etoposide
11 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
12 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
13 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
14 Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis Completed NCT00142233 Phase 3 Magnesium
15 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
16 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Carboplatin;Cisplatin;Etoposide
17 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
18 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
19 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
20 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
21 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
22 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
23 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
24 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
25 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
26 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
27 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
28 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
29 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
30 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
31 Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients Completed NCT00423852 Phase 1, Phase 2 carboplatin;ifosfamide;paclitaxel
32 Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies Completed NCT00036842 Phase 2 arsenic trioxide
33 PHASE I/II TRIAL OF TAXOL, IFOSFAMIDE, AND CISPLATIN FOR CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH FAVORABLE PROGNOSTIC FEATURES Completed NCT00002559 Phase 1, Phase 2 cisplatin;ifosfamide;paclitaxel
34 High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
35 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
36 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
37 PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER Completed NCT00002903 Phase 2 docetaxel
38 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
39 Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
40 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
41 Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors Completed NCT00006043 Phase 2 temozolomide
42 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
43 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
44 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
45 High-Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Malignancies Refractory to Conventional Chemotherapy Completed NCT00003173 Phase 2 thiotepa
46 PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES Completed NCT00002558 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
47 INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE Completed NCT00002508 Phase 1, Phase 2 carboplatin;etoposide
48 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
49 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
50 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate

Search NIH Clinical Center for Testicular Germ Cell Tumor

Genetic Tests for Testicular Germ Cell Tumor

Anatomical Context for Testicular Germ Cell Tumor

Organs/tissues related to Testicular Germ Cell Tumor:

MalaCards : Testis, Pineal, Lymph Node, Bone Marrow, T Cells, Spinal Cord, Bone

Publications for Testicular Germ Cell Tumor

Articles related to Testicular Germ Cell Tumor:

(show top 50) (show all 9089)
# Title Authors PMID Year
1
Activating c-kit gene mutations in human germ cell tumors. 62 57 5
10362788 1999
2
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 57 5
19855393 2009
3
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 57 5
10408400 1999
4
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 57 5
10380920 1999
5
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 57 5
9989495 1999
6
Rare de novo germline copy-number variation in testicular cancer. 62 57
22863192 2012
7
Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. 62 57
21617256 2011
8
Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. 62 57
20543847 2010
9
Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. 62 57
20228134 2010
10
LINE-1 methylation is inherited in familial testicular cancer kindreds. 62 57
20478068 2010
11
A genome-wide association study of testicular germ cell tumor. 62 57
19483681 2009
12
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. 62 57
19483682 2009
13
Deletion of eIF2beta suppresses testicular cancer incidence and causes recessive lethality in agouti-yellow mice. 62 57
19168544 2009
14
Increased prevalence of testicular microlithiasis in men with familial testicular cancer and their relatives. 62 57
18841155 2008
15
Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. 62 57
17971766 2007
16
Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients. 62 57
16229939 2006
17
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. 62 57
16380914 2005
18
The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. 62 57
15902260 2005
19
Mutations of BRAF and RAS are rare events in germ cell tumours. 62 57
15386408 2005
20
A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13. 62 57
10890890 2000
21
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. 62 57
10655070 2000
22
Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain. 62 57
10508525 1999
23
Familial testicular cancer in Norway and southern Sweden. 62 57
8611416 1996
24
Occurrence of seminoma and dysgerminoma in father and daughter. 62 57
8204448 1994
25
Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. 62 57
1739626 1992
26
Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. 62 57
2177638 1990
27
Familial testicular teratoma in 2 children: familial report and review of the literature. 62 57
7365898 1980
28
Father-son testicular malignancy. Does genetic anticipation occur? 62 57
7260832 1980
29
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 5
16752380 2006
30
Cytogenetic and molecular analysis of a family with three brothers afflicted with germ-cell cancer. 57
15032972 2004
31
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. 5
12727991 2003
32
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 5
12624096 2003
33
Curing metastatic testicular cancer. 57
11904381 2002
34
Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. 57
11912161 2002
35
BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumors. 57
11376806 2001
36
Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. 57
10582682 1999
37
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 5
9677066 1998
38
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. 57
9605748 1998
39
A genetic perspective of male germ cell tumors. 57
9562446 1998
40
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 5
9207791 1997
41
Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors. 57
8812492 1996
42
Familial predisposition to both male and female germ cell tumours? 57
8825060 1996
43
DNA pooling as a quick method for finding candidate linkages in multigenic trait analysis: an example involving susceptibility to germ cell tumors. 57
8903734 1996
44
Candidate regions for a testicular cancer susceptibility gene. 57
8541838 1995
45
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 5
7773297 1995
46
Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. 57
7954476 1994
47
The ter primordial germ cell deficiency mutation maps near Grl-1 on mouse chromosome 18. 57
8043946 1994
48
A mutation in the Ter gene causing increased susceptibility to testicular teratomas maps to mouse chromosome 18. 57
8054975 1994
49
Chromosome 12 in human testicular cancer: dosage changes and their parental origin. 57
1458445 1992
50
Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors. 57
1332066 1992

Variations for Testicular Germ Cell Tumor

ClinVar genetic disease variations for Testicular Germ Cell Tumor:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs) DUP Pathogenic
6250 rs387906350 GRCh37: 1:85733512-85733513
GRCh38: 1:85267829-85267830
2 KIT NM_000222.3(KIT):c.2446G>C (p.Asp816His) SNV Pathogenic
13863 rs121913506 GRCh37: 4:55599320-55599320
GRCh38: 4:54733154-54733154
3 HRAS, LRRC56 NM_005343.4(HRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic
12601 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
4 STK11 NM_000455.5(STK11):c.812del (p.Ser271fs) DEL Pathogenic
1184620 GRCh37: 19:1221289-1221289
GRCh38: 19:1221290-1221290
5 FGFR3 NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu) SNV Pathogenic
16331 rs78311289 GRCh37: 4:1807889-1807889
GRCh38: 4:1806162-1806162
6 BCL10 NM_003921.5(BCL10):c.172C>T (p.Arg58Ter) SNV Pathogenic
6266 rs121918314 GRCh37: 1:85736475-85736475
GRCh38: 1:85270792-85270792
7 BCL10 NM_003921.5(BCL10):c.172C>G (p.Arg58Gly) SNV Pathogenic
6265 rs121918314 GRCh37: 1:85736475-85736475
GRCh38: 1:85270792-85270792

UniProtKB/Swiss-Prot genetic disease variations for Testicular Germ Cell Tumor:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Lys650Glu VAR_004160 rs78311289
2 STK10 p.Lys277Glu VAR_023827 rs757545210
3 STK11 p.Gly163Asp VAR_033140 rs137853078

Copy number variations for Testicular Germ Cell Tumor from CNVD:

6 (show all 12)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19332 1 149600000 247249719 Gain Testicular germ cell tumor
2 42821 10 40300000 82000000 Loss Testicular germ cell tumor
3 61421 12 1 132349534 Gain Testicular germ cell tumor
4 89303 15 17000000 76100000 Loss Testicular germ cell tumor
5 121721 18 46400000 76117153 Loss Testicular germ cell tumor
6 146937 2 56300000 230700000 Loss Testicular germ cell tumor
7 180589 4 107900000 191273063 Loss Testicular germ cell tumor
8 206877 6 149100000 170899992 Loss Testicular germ cell tumor
9 226157 7 55086724 55275030 Amplification EGFR Testicular germ cell tumor
10 245111 9 101600000 129300000 Loss Testicular germ cell tumor
11 261703 X 24900000 29400000 Gain Testicular germ cell tumor
12 262543 X 37500000 146900000 Gain Testicular germ cell tumor

Expression for Testicular Germ Cell Tumor

Search GEO for disease gene expression data for Testicular Germ Cell Tumor.

Pathways for Testicular Germ Cell Tumor

GO Terms for Testicular Germ Cell Tumor

Cellular components related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.4 MIR367 MIR302D MIR200C MIR145 MIR140 MIR133B

Biological processes related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 10.03 STK11 STK10 KIT FGFR3
2 miRNA-mediated gene silencing GO:0035195 9.89 MIR373 MIR372 MIR371A MIR367 MIR302D MIR200C
3 positive regulation of phospholipase C activity GO:0010863 9.76 KIT HRAS
4 positive regulation of mast cell cytokine production GO:0032765 9.67 BCL10 KIT
5 mast cell proliferation GO:0070662 9.62 KIT KITLG
6 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.58 MIR200C MIR145 MIR133B
7 positive regulation of mast cell proliferation GO:0070668 9.56 KIT KITLG
8 melanocyte migration GO:0097324 9.46 KITLG KIT
9 negative regulation of vascular endothelial growth factor production GO:1904046 8.92 MIR373 MIR372 MIR302D MIR140

Molecular functions related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.26 MIR200C MIR145 MIR140 MIR133B
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR373 MIR372 MIR371A MIR302D MIR200C MIR145

Sources for Testicular Germ Cell Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....